Real-World Data on the Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced/Metastatic Breast Cancer
Αntria Savvidou, Anastasia Constantinidou, Lefteris Zacharia, Kyriaki Michailidou, Μaria Zanti, Stavroula Kitiri, Yiola Marcou, Ifigenia Konstantinou, Eleni Kakouri, Myria Galazi, Christos Petrou · 2026
Read Real-World Data on the Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced/Metastatic Breast Cancer by Αntria Savvidou, Anastasia Constantinidou, Lefteris Zacharia, Kyriaki Michailidou, Μaria Zanti, Stavroula Kitiri, Yiola Marcou, Ifigenia Konstantinou, Eleni Kakouri, Myria Galazi, Christos Petrou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13171272.txt.
Description
Drugs that stall cell division have changed advanced breast cancer care, and a 2026 study from Cyprus checks how they perform off the trial stage. The patients have hormone-sensitive, HER2-negative cancer that has spread or advanced, and the drugs are CDK4/6 inhibitors paired with hormone therapy.
The retrospective arm covered 269 patients treated from 2018 to 2021 with one of three such drugs, in first, second, or third line. Seventy patients still on treatment then joined a prospective follow-up through 2024, watched in real time. Safety and effectiveness were compared against trial results and other real-world series. Single-center evidence like this tests whether trial benefits survive contact with ordinary clinics.
Catalog record
| CREATOR | Αntria Savvidou, Anastasia Constantinidou, Lefteris Zacharia, Kyriaki Michailidou, Μaria Zanti, Stavroula Kitiri, Yiola Marcou, Ifigenia Konstantinou, Eleni Kakouri, Myria Galazi, Christos Petrou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |